APUS
Apimeds Pharmaceuticals US, Inc.
NYSE MKT: APUS · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$1.88
+0.00% today
Updated 2026-04-29
Market cap
$2.36M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.41
Dividend yield
—
52W range
$1 – $4
Volume
0.1M
Apimeds Pharmaceuticals US, Inc. (APUS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — |
| Cost of revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Gross margin | — | — | — | — |
| R&D | $489939.00 | $368000.00 | $98544.00 | $0.00 |
| SG&A | $529555.00 | $271529.00 | $648892.00 | $1.28M |
| Operating income | $-1.02M | $-639529.00 | $-747436.00 | $-1.28M |
| Operating margin | — | — | — | — |
| EBITDA | $-1.02M | $-639529.00 | $-739625.00 | $-1.27M |
| EBITDA margin | — | — | — | — |
| EBIT | — | — | — | — |
| Interest expense | $6740.00 | $29137.00 | $38069.00 | $117719.00 |
| Income tax | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-1.03M | $-668666.00 | $-777694.00 | $-1.39M |
| Net income growth (YoY) | — | +34.8% | -16.3% | -78.7% |
| Profit margin | — | — | — | — |